BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18987663)

  • 1. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
    Burger JA; Peled A
    Leukemia; 2009 Jan; 23(1):43-52. PubMed ID: 18987663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
    Burger JA; Stewart DJ; Wald O; Peled A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 chemokine receptor antagonists: perspectives in SCLC.
    Burger JA; Stewart DJ
    Expert Opin Investig Drugs; 2009 Apr; 18(4):481-90. PubMed ID: 19335276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
    Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
    Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
    Tavor S; Petit I
    Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
    Cho BS; Kim HJ; Konopleva M
    Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
    Peled A; Tavor S
    Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
    Zhou Y; Cao HB; Li WJ; Zhao L
    Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
    Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
    Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
    Scala S
    Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
    Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
    Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
    Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
    Shen ZH; Zeng DF; Kong PY; Ma YY; Zhang X
    Blood Cells Mol Dis; 2016 Jul; 59():16-24. PubMed ID: 27282562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
    Burger JA; Kipps TJ
    Blood; 2006 Mar; 107(5):1761-7. PubMed ID: 16269611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.
    Randhawa S; Cho BS; Ghosh D; Sivina M; Koehrer S; Müschen M; Peled A; Davis RE; Konopleva M; Burger JA
    Br J Haematol; 2016 Aug; 174(3):425-36. PubMed ID: 27071778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
    Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
    Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
    Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
    Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL12 (SDF-1)/CXCR4 pathway in cancer.
    Teicher BA; Fricker SP
    Clin Cancer Res; 2010 Jun; 16(11):2927-31. PubMed ID: 20484021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
    Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.